Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Prinz, Christian ^a   Vasyutina, Elena ^a   Lohmann, Gregor ^a   Schrader, Alexandra ^a   Romanski, Steffen ^a   Hirschhäuser, Christoph ^a   Mayer, Petra ^a   Frias, Corazon ^b   Herling, Carmen D ^c   Hallek, Michael ^c   Schmalz, Hans Günther ^a   Prokop, Aram ^b   Mougiakakos, Dimitrios ^d   Herling, Marco ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CLL; Mitochondrial respiration; Organometallic nucleosides; ROS; TCL1

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENDAMUSTINE; CASPASE; CYTOCHROME C; FERROCENE; FLUDARABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEIC ACID BASE; NUCLEOSIDE; ORGANOMETALLIC NUCLEOSIDE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RUTHENOCENE DERIVATIVE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG; CASPASE 3; ONCOPROTEIN; ORGANOMETALLIC COMPOUND; TCL1A PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BIOENERGY; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; GENE TARGETING; HIGH RISK POPULATION; HUMAN; LEUKEMIA CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATION REDUCTION REACTION; OXYGEN CONSUMPTION; SPLEEN CELL; T CELL LEUKEMIA; AUTOPHAGY; CHEMISTRY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; HOMEOSTASIS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROSIS; ONCOGENE; PATHOLOGY; RISK FACTOR; STROMA CELL; TUMOR CELL LINE;

MURINAE;

APOPTOSIS; AUTOPHAGY; CASPASE 3; CELL LINE, TUMOR; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NECROSIS; NUCLEOSIDES; ONCOGENES; ORGANOMETALLIC COMPOUNDS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; RISK FACTORS; STROMAL CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930625749     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0378-1     Document Type: Article

References (54)

1. Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99:965-72.
2. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-74.
3. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6:405-18.
4. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367-75.
5. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma. 2009;50:510-3.
6. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-6.
7. Doering M, Ba LA, Lilienthal N, Nicco C, Scherer C, Abbas M, et al. Synthesis and selective anticancer activity of organochalcogen based redox catalysts. J Med Chem. 2010;53:6954-63.
8. Lilienthal N, Prinz C, Peer-Zada AA, Doering M, Ba LA, Hallek M, et al. Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic "sensor/effector" compounds. Leuk Lymphoma. 2011;52:1407-11.
9. Biswas S, Zhao X, Mone AP, Mo X, Vargo M, Jarjoura D, et al. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res. 2010;34:925-31.
10. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7:97-110.
11. Chen G, Chen Z, Hu Y, Huang P. Inhibition of mitochondrial respiration and rapid depletion of mitochondrial glutathione by β-phenethyl isothiocyanate: mechanisms for anti-leukemia activity. Antioxid Redox Signal. 2011;15:2911-21.
12. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene. 2011;30:701-13.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
14. Capasso M, Bhamrah MK, Henley T, Boyd RS, Langlais C, Cain K, et al. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol. 2010;11:265-72.
15. Wheeler ML, Defranco AL. Prolonged production of reactive oxygen species in response to B cell receptor stimulation promotes B cell activation and proliferation. J Immunol. 2012;189:4405-16.
16. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ. 2003;10:477-84.
17. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14:276-86.
18. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99:6955-60.
19. Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009;114:4675-86.
20. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20:280-5.
21. Schlawe D, Majdalani A, Velcicky J, Hessler E, Wieder T, Prokop A, et al. Iron-containing nucleoside analogues with pronounced apoptosis-inducing activity. Angew Chem Int Ed Engl. 2004;43:1731-4.
22. James P, Neudörfl J, Eissmann M, Jesse P, Prokop A, Schmalz H-G. Enantioselective synthesis of ferrocenyl nucleoside analogues with apoptosis-inducing activity. Org Lett. 2006;8:2763-6.
23. 3 substructure: stereoselective synthesis, configurational assignment, and apoptosis-inducing activity. Chem Eur J. 2013;19:13017-29.
24. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.
25. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114:4441-50.
26. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, et al. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia. 2012;26:1812-20.
27. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.
28. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ. 2005;12 Suppl 2:1528-34.
29. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209-23.
30. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 2010;8:31.
31. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene. 2004;23:2785-96.
32. Taiwo FA: Mechanism of tiron as scavenger of superoxide ions and free electrons. Spectrosc. 2008;22(6):491-98.
33. Sun S-Y. N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol Ther. 2010;9:109-10.
34. Jitschin R, Hofmann AD, Bruns H, Gießl A, Bricks J, Berger J, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014;123:2663-72.
35. Noguchi M, Ropars V, Roumestand C, Suizu F. Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB. 2007;21:2273-84.
36. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931-47.
37. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105:19643-8.
38. Ropars V, Despouy G, Stern M-H, Benichou S, Roumestand C, Arold ST. The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. PLoS One. 2009;4, e6567.
39. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JPR, Melendez-Zajgla J. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res. 2008;27:48.
40. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-89.
41. Nguyen HV, Sallustrau A, Balzarini J, Bedford MR, Eden JC, Georgousi N, et al. Organometallic nucleoside analogues with ferrocenyl linker groups: synthesis and cancer cell line studies. J Med Chem. 2014;57:5817-22.
42. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25:799-804.
43. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008;112:1912-22.
44. Nogueira V, Park Y, Chen C-C, Xu P-Z, Chen M-L, Tonic I, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell. 2008;14:458-70.
45. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, et al. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Blood. 2012;119:180-7.
46. Guo Z, Deshpande R, Paull TT. ATM activation in the presence of oxidative stress. Cell Cycle. 2010;9:4805-11.
47. Popal W, Boucas J, Peer-Zada AA, Herling M. Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:1375-8.
48. Herling M, Patel KA, Hsi ED, Chang K-C, Rassidakis GZ, Ford R, et al. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol. 2007;31:1123-9.
49. Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111:328-37.
50. Hong X, Song R, Song H, Zheng T, Wang J, Liang Y, et al. PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 2013;1-13.
51. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
52. Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood. 2013;121:4126-36.
53. Lanemo Myhrinder A, Hellqvist E, Bergh A-C, Jansson M, Nilsson K, Hultman P, et al. Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1769-79.
54. Schrader A, Popal W, Lilienthal N, Crispatzu G, Mayer P, Jones D, et al. AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1. Curr Cancer Drug Targets. 2014;14:700-12.